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Dopamine D2/3- and μ-opioid receptor antagonists reduce
cue-induced responding and reward impulsivity in humans
SC Weber1, B Beck-Schimmer2, M-E Kajdi2, D Müller3, PN Tobler1,4,6 and BB Quednow4,5,6
Increased responding to drug-associated stimuli (cue reactivity) and an inability to tolerate delayed gratiﬁcation (reward
impulsivity) have been implicated in the development and maintenance of drug addiction. Whereas data from animal studies
suggest that both the dopamine and opioid system are involved in these two reward-related processes, their role in humans is less
clear. Moreover, dopaminergic and opioidergic drugs have not been directly compared with regard to these functions, even though
a deeper understanding of the underlying mechanisms might inform the development of speciﬁc treatments for elevated cue
reactivity and reward impulsivity. In a randomized, double-blind, between-subject design we administered the selective dopamine
D2/D3 receptor antagonist amisulpride (400 mg, n= 41), the unspeciﬁc opioid receptor antagonist naltrexone (50 mg, n= 40) or
placebo (n= 40) to healthy humans and measured cue-induced responding with a Pavlovian-instrumental transfer task and reward
impulsivity with a delay discounting task. Mood was assessed using a visual analogue scale. Compared with placebo, amisulpride
signiﬁcantly suppressed cue-induced responding and reward impulsivity. The effects of naltrexone were similar, although less
pronounced. Both amisulpride and naltrexone decreased average mood ratings compared with placebo. Our results demonstrate
that a selective blockade of dopamine D2/D3 receptors reduces cue-induced responding and reward impulsivity in healthy humans.
Antagonizing μ-opioid receptors has similar effects for cue-induced responding and to a lesser extent for reward impulsivity.
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INTRODUCTION
Substance addiction is characterized by uncontrolled drug use,
drug craving and a high incidence of relapse even after years of
abstinence. Cue reactivity and reward impulsivity are two core
features of addiction that have an important role in the
development and maintenance of drug addiction as well as
relapse.1 Cue reactivity refers to the ability of drug-associated
stimuli to increase responding to those drug cues in addiction. It is
often used to explain why patients with addiction use drugs and
relapse at a higher rate in environments that have been associated
with prior drug use. Objects and environments that are paired
with drug use become conditioned stimuli capable of indepen-
dently triggering instrumental drug-seeking behaviors.1 Not
surprisingly, elevated cue reactivity is consistently found in
substance-use disorders.2,3 Reward impulsivity is deﬁned as the
inability to delay gratiﬁcation and wait for a larger reward, in the
face of a smaller immediate reward.4 Increased reward impulsivity
has been suggested as a stable marker (endophenotype) of
addiction4–7 and may explain the reduced ability of affected
individuals to refrain from taking drugs even when continued use
is associated with high personal and ﬁnancial costs.
As both cue reactivity and reward impulsivity are important
factors in drug addiction, understanding their underlying neuro-
chemistry may provide key insights into drug abuse and relapse.
Two neurotransmitter systems have been particularly implicated
in addiction—the dopamine and the opioid systems.8 Opioid
receptor agonists and antagonists are commonly prescribed to
reduce craving and to prevent relapse in opioid dependence and
other forms of substance addiction.9 On the other hand, in animal
models, most addictive drugs increase dopamine levels in the
nucleus accumbens,10 which has been conﬁrmed in humans for
stimulant drugs, alcohol and nicotine.11 Moreover, stimulant-
addicted individuals show a blunted dopamine response to acute
challenges with stimulants, but increased dopamine release in
response to sensory cues associated with drug use.12 It is therefore
of high interest to understand how cue reactivity and reward
impulsivity are commonly and differentially inﬂuenced by
dopamine and opioid blockade.
Here, we investigate the pharmacological basis of cue reactivity
and reward impulsivity in healthy volunteers. The use of healthy
volunteers to study how reward processing may be altered in
addiction offers several important beneﬁts. First, it makes human
studies comparable to the numerous animal studies that mainly
use pharmacological manipulations on healthy animal subjects.
Second, using healthy volunteers makes it easier to interpret the
results of the pharmacological intervention, as it dissociates drug
effects from disorder effects and is not complicated by interac-
tions between drug and disorder. Third, patients with substance-
use disorders often have comorbidities and are treated with
psychotropic medications that potentially interact with experi-
mental drug challenge effects. In the current study, we probe the
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effect of dopamine and opioid receptor antagonists in a
Pavlovian-instrumental transfer (PIT) task and a delay-
discounting task. PIT is a common measure of cue-induced
responding (cue reactivity) that has been used in numerous
animal studies and has also been applied to humans.13 It
measures the ability of a previously rewarded conditioned
stimulus to trigger instrumental responding even in the absence
of any rewards. PIT tasks usually employ a three-phase design: in
an instrumental and a Pavlovian phase, an instrumental response
to earn reward is acquired and a Pavlovian conditioned stimulus
predicting reward is learned. During the critical test phase, which
measures PIT/cue-induced responding, the conditioned stimulus is
displayed in the absence of rewards and instrumental responding
is recorded. The ability of the conditioned stimulus to elicit
instrumental responding during the test phase is considered a
model of how drug-associated stimuli can trigger drug-seeking
behavior.14 Reward impulsivity is often measured using delay-
discounting tasks.4,15,16 In these tasks, participants choose
between smaller immediate rewards and larger delayed rewards,
and reward impulsivity is characterized by an increased preference
for smaller immediate rewards over larger delayed rewards, that is,
higher discounting.4,15,16
In separate studies, PIT and delay discounting have been linked
to the dopamine system (delay discounting: for example 17–19;
PIT: for example 20–24) and the opioid system (delay discounting:
for example 25–27; PIT: for example 28,29). However, the previous
results are primarily from animal studies (for a non-exhaustive
overview, see Table 1) and often contradictory because various
and relatively unselective challenge drugs have been used. In
addition, the rare human studies (Table 1) have mostly tested
rather small samples. More importantly, no study directly
compared dopaminergic and opioidergic drug challenges on
reward impulsivity and cue-induced responding.
To ﬁll this gap, we investigated the role of the dopamine and
opioid systems in cue-induced responding and reward impulsivity
by administering the highly selective D2/D3 receptor antagonist
amisulpride, the non-selective opioid antagonist naltrexone and
placebo in a randomized, double-blind, between-subject design in
healthy volunteers. We used 400 mg amisulpride and 50 mg
naltrexone administered orally, a standard dosage with only minor
side effects in several previous studies.40,41
MATERIALS AND METHODS
Participants
A total of 121 healthy volunteers, recruited from the Laboratory for Social
and Neural Systems Research subject pool, participated in the study. The
sample size was chosen based on previous literature and in order to obtain
a statistical power of 80% for detecting signiﬁcant differences between
drug conditions.41 All participants were screened by the recruitment team
to ensure that they were physically and psychiatrically healthy. Speciﬁc
exclusion criteria were a history of brain disease or injury, surgery to head
or heart, neurological or psychiatric diseases (including alcoholism,
depression, schizophrenia, bipolar disorders, claustrophobia or Parkinson
symptoms), a severe medical disease such as diabetes, cancer, insufﬁciency
of liver or kidneys, acute hepatitis, high or low blood pressure, any
cardiovascular incidences, epilepsy, pregnancy or breastfeeding, past use
of opiates or other drugs that may interact with amisulpride or naltrexone
(such as stimulants). Illegal drug use (amphetamines, barbiturates,
buprenorphine, benzodiazepines, cannabis, cocaine, MDMA, methadone
and morphine/opiates) was controlled by drug urine testing (M-10/5-DT,
Diagnostik Nord, Schwerin, Germany) and cardiac health was conﬁrmed by
electrocardiogram. All participants provided written informed consent. The
study was approved by the ethics committee of the canton of Zurich and
registered on www.clinicaltrials.gov (NCT02557984).
Procedure
On average, 3 h (±1.10 min, s.e.m.) before the experimental tasks,
participants received a pill containing either placebo (N=40), 400 mg
amisulpride (N= 41) or 50 mg naltrexone (N= 40) in a randomized and
double-blind manner (Supplementary Figure S1). Randomization was
performed in blocks of nine participants by the study pharmacist.
Amisulpride is a selective dopamine D2/D3 receptor antagonist, whereas
naltrexone is an unspeciﬁc opioid receptor antagonist that acts primarily
on the μ- and κ-opioid receptors, with lesser and more variable effects on
δ-opioid receptors.41,42 The two active doses were chosen to result in
comparable neurochemical responses. Whereas 400 mg amisulpride
usually result in ~ 50–80% D2 receptor occupancy,43–46 50 mg naltrexone
normally cause 490% mu-opioid receptor occupancy.42,47 As D2 receptor
occupancies of 490% are only attainable with amisulpride doses of
800 mg or higher,43,45,46 we nevertheless decided to compare 400 mg
amisulpride and 50 mg naltrexone—doses that are both well tolerated in
healthy subjects40,41—in order to avoid extrapyramidal side effects
potentially associated with higher amisulpride doses. To enhance and
equate absorption time across participants, all participants were asked not
to eat for 6 h before arrival. After task completion, participants answered
post-experimental questionnaires, which probed whether they thought
they had received a drug or placebo, and also measured their mood (one
rating was not recorded in the placebo group). Using high-performance
liquid chromatography–mass spectrometry, amisulpride and naltrexone
blood plasma levels immediately before and after the behavioral tasks
were determined in order to control for absorption of the drugs
(amisulpride before: 618 μg l− 1, after: 915 μg l− 1, mean: 767 μg l− 1;
naltrexone before: 2.98 μg l− 1, after: 2.50 μg l− 1, mean: 2.74 μg l− 1). There
was no correlation between the blood plasma level and task performance
(PIT: |r|o0.20, P40.24, Namisulpride = 35, Nnaltrexone = 34; DD: |r|o0.15,
P40.36, Namisulpride = 40, Nnaltrexone = 40).
PIT task
The PIT task (duration: 23.46 min ± 0.42) followed the standard three-phase
PIT design (please refer to the supplement for a more detailed description)
according to the protocol of Lovibond and Colagiuri.48 Initially, in the
instrumental conditioning phase, participants needed to press a button in
order to earn a chocolate M&M's reward on a variable-ratio 10 schedule.
Subsequently, in the Pavlovian phase, a differential-conditioning proce-
dure was used in which an appetitively conditioned stimulus (CS+) was
always paired with the delivery of a chocolate M&M's reward, whereas a
neutral stimulus (CS-) was always presented with no outcome. Lastly,
participants completed the transfer-test phase, where no rewards were
available. Both the CS+ and the CS- were presented twice for 10 s in
random order, while button presses were recorded (Supplementary
Figure S2). Before and after the task, participants were asked to indicate
their desire for M&M's in order to control for hunger levels. Using the same
standard as in the previous study,48 two placebo, six amisulpride and six
naltrexone participants did not meet the criterion of the instrumental
phase and were therefore excluded from the PIT analysis. For an overview
of excluded subjects for each task, please refer to Supplementary Table S1.
Delay-discounting task
After the PIT task, participants completed the Kirby (1999) Monetary Choice
Questionnaire15 to measure delay discounting (duration: 1.8 min ± 0.04).
The questionnaire consisted of 27 hypothetical decisions in which
participants chose between a smaller, immediate monetary reward and a
larger, delayed monetary reward. It included nine questions for each of
three delayed reward magnitudes (small, medium and large). The
monetary rewards varied between 11 Swiss Frank (CHF) and 80 CHF for
immediate rewards, and between 25 CHF and 85 CHF for delayed rewards.
The delays of the delayed reward varied between 7 and 186 days. One
female subject in the amisulpride group did not complete the delay-
discounting task and was therefore excluded from all analyses of this task.
Assessment of affect, mood and trait impulsivity
Before drug administration, participants completed the Barratt Impulsive-
ness Scale (BIS-11)49 in order to measure trait impulsivity, the short version
of the Action Regulating Emotion Systems questionnaire50 to check for
differences in the Behavioral Inhibition and the Behavioral Activation
System scales (BIS/BAS), as well as the Affect Intensity Measure51 to assess
affective responsiveness.
After the behavioral tasks, participants rated their current mood on the
computer using a visual analogue scale that ranged from 0 (very bad
mood) to 100 (very good mood). They were instructed to ‘please mark on
the scale how you feel right now.’
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Table 1. Human and selected animal studies investigating the role of dopamine and opioid in cue-induced responding and reward impulsivity
Substance Dosage N Effect Reference
CUE-INDUCED RESPONDING
Dopamine
Animal
D2/3 antagonist Pimozide 0.25 mg kg− 1 i.p. 32(B) ↓ 20
α-Flupenthixol 0.5 mg kg− 1 i.p. 32(B) ↓ 20
Flupenthixol 0.5 mg kg− 1 i.p. 24 ↓ 23
Flupenthixol 0.05 and 0.25 mg kg− 1 i.p. 14 ↓(0.25 mg kg− 1)
↔ (0.05 mg kg− 1)
23
Flupenthixol 0.5 mg kg− 1 i.p. 16 ↓ 24
Raclopride 0.5- and 1.0 μg Intra-NAC 57(B) ↓ 22
D1 antagonist SCH-23390 0.5- and 0.75 μg Intra-NAC 56(B) ↓ 22
Indirect DA agonist Amphetamine 20 μg per 0.2 μl intra-NAC 45 ↑ 29
Amphetamine 20 μg per 0.2 μl intra-NAC 14 ↑ 30
Amphetamine 0.0, 2.0, 10.0 or 20.0 μg per
0.5 μl Intra-NAC
30 ↑ 31
Human
DA/NA depletion Amino-acid mixture
lacking TYR/PHE
90 g 69(B) ↓ 21
Opioid
Animal
Mu-opioid receptor
antagonist
CTAP 2 μg μl− 1 Intra-NAC 48 ↔ 28
Delta-opioid receptor
antagonist
Naltrindole 5 μg μl− 1 Intra-NAC 48 ↓(For NAc shell) ↔ (for Nac
core)
28
Mu-opioid receptor
agonist
DAMGO 0.5 μg per 0.2 μl Intra-NAC 55 ↑ 29
Human
Unspeciﬁc opioid
receptor antagonist
Naltrexone 50 mg p.o. 23(B) ↔ (Craving)
↓(fMRI)
32
REWARD IMPULSIVITY
Dopamine
Animal
D2/3 antagonist Flupenthixol 0.5 mg kg− 1 i.p. 8 ↑ 18
Flupenthixol 25, 50 and 100 μg kg− 1 i.p. 17 ↓ 33
Haloperidol 0.01–0.1 mg kg− 1 i.p. 24 ↔ 34
Raclopride 40, 80 and 120 μg kg− 1 i.p. 17 ↓ 33
D1 antagonist SCH-23390 5, 10 and 20 μg kg− 1 i.p. 17 ↔ 33
Indirect DA agonist Amphetamine 0.5 and 1.0 mg kg− 1 i.p. 17 ↑ 33
D-Amphetamine 0.4–1.2 mg kg− 1 s.c. 24 ↑ 34
D-Amphetamine 0.25 and 0.5 mg kg− 1 i.p. 8 ↓(0.25 mg kg− 1)
↔ (0.5 mg kg− 1)
18
D-Amphetamine 0.80 and 1.20 mg kg− 1 i.p. 24 ↑ 35
Cocaine 15 mg kg− 1 i.p. 5 ↑ 36
Human
D2/3 antagonist Haloperidol 1.5 mg p.o. 13 ↔ 19
D2/3 agonist Oramipexole 0.25 and 0.5 mg p.o. 10 ↔ 37
Indirect DA agonist D-Amphetamine 10 mg or 20 mg p.o. 36 ↓(20 mg) ↔ (10 mg) 17
L-dopa 150 mg p.o. 13 ↑ 19
Opioid
Animal
Unspeciﬁc opioid
receptor antagonist
Naloxone 0.3, 1.0 and 3.0 mg kg− 1 i.p. 16 ↔ 27
Naltrexone 0.01, 0.1, 1.0 and 10 mg kg− 1
s.c.
15 ↔ 25
Mu-opioid receptor
agonist
Morphine 0.3, 1.0, and 1.8 mg kg− 1 s.c. 15 ↑ 25
Morphine 0.3, 1.0, 3.0 and 6.0 mg kg− 1
i.p.
16 ↑(6.0 mg kg−1) 27
Human
Unspeciﬁc opioid
receptor antagonist
Naltrexone 50 mg p.o. 18 ↔ 38
Abbreviations: DA, dopamine; fMRI, functional magnetic resonance imaging; i.p., intraperitoneal injection, intra-NAC, intra nucleus accumbens microinjections;
N, number of subjects; NA, noradrenaline; p.o., per oral administration; s.c., subcutaneous injection; TYR/PHE, tyrosine/phenylalanine. All studies are within-
subject, unless marked ‘B’ (between subject). Effects are abbreviated as: ↓= decrease,↔ = no effect, ↑= increase. As the present study focused on cue-
induced responding and reward impulsivity in humans, only representative animal studies are listed. For a more exhaustive review please refer to Holmes
et al.13 and Bari and Robbins.39
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Statistical analysis
To assess whether our groups differed in age, body mass index, years of
education, trait impulsivity, BIS/BAS score and affect intensity, we
conducted one-way analyses of variance (ANOVAs) with these measures.
In addition, we performed a Χ2-analysis of whether the subjects correctly
guessed whether they received a medication or placebo.
In order to assess Pavlovian and instrumental learning, we analyzed the
performance of the groups in the ﬁrst two phases of the PIT task, using
Figure 1. Button presses during the transfer-test phase of the Pavlovian-instrumental transfer task. (a–c) Button presses in 5-s bins before,
during, and after presentation of the conditioned stimuli (CSs) for participants in the (a) placebo, (b) amisulpride and (c) naltrexone groups.
The CS+ had previously been paired with chocolate; the CS− had not been paired with chocolate. The dotted lines indicate the pre-CS phase
(−10 to 0 s) and the onset and offset of the CS phase (0–10 s). (d–f) The mean number of button presses in the pre-CS phase and the CS phase
for participants in the (d) placebo, (e) amisulpride and (f) naltrexone groups (**Po0.005). The CS+ is displayed in dark and the CS− in light
colors. Error bars represent s.e.m.'s.
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one-way ANOVAs with the between-subject factor drug group. Speciﬁcally,
we compared the number and frequency of button presses, the time
participants took to reach the criterion for the instrumental phase and the
ratings of the reward contingencies for the Pavlovian phase. For the main
analysis of interest, we focused on differences in the number of button
presses during the transfer-test phase. We normalized the button presses
during the CS test phase by the number of responses during the initial
extinction period of the transfer-test phase. However, the results did not
change when the raw (non-normalized) data were used and the groups
did not differ signiﬁcantly in button-pressing during the extinction period
(Supplementary Table S2). In order to probe the cue-related increase in
instrumental responding, we compared button presses during the 10-s CS
presentation with the button presses in the 10 s before the CS
presentation for CS+ versus CS− . We performed a mixed-model ANOVA
to compare the two drug groups with the placebo group, with group as
the between-subject factor and CS type and time as the within-subject
factors. Signiﬁcant ﬁndings (Po0.05) were followed by post hoc t-test
analyses.
For the delay-discounting task we measured how often participants
chose the smaller immediate reward, as opposed to the larger delayed
reward to estimate reward discounting. More frequent choice of
immediate rewards corresponds to stronger discounting. This use of the
proportion of immediate rewards chosen allowed us to analyze the
discounting behavior without relying on assumptions about the shape of
the discounting curve for the individual participants.52 However, using
Kirby’s estimation to determine the k-values of the individuals,15 or using
logistic regression,53 did not change the pattern of results (Supplementary
Table S3). The proportion of immediate rewards chosen for each of the
three groups was contrasted using a one-way ANOVA for all rewards, as
well as a repeated-measures ANOVA to include the within-subject factor
reward magnitude. As with the PIT task, signiﬁcant ﬁndings (Po0.05) were
followed by post hoc t-test analyses.
In addition, using Pearson correlations we investigated how closely
related the behaviors of the participants in the two tasks were and, in an
exploratory analysis, how mood was related to task performance.
RESULTS
The three groups did not differ in age, body mass index, years of
education, trait impulsivity, BIS/BAS scores and affect intensity (one-
way ANOVAs, all F(2,118)o1.86, P40.16; Supplementary Table S4).
Furthermore, participants were unaware whether they received one
of the drugs or placebo, as assessed by post-experimental
questionnaires (χ2(1) = 1.00, P=0.32).
PIT
To assess cue-induced responding, we compared the number of
button presses during the transfer-test phase. Contrasting CS-
induced button presses against pre-CS responding revealed a
signiﬁcant effect of time (F(1,104) = 5.99, Po0.05). There was also
a signiﬁcant main effect of the CS type, with the rewarded CS
increasing button presses in contrast to the unrewarded CS (F
(1,104) = 18.54, Po0.0001). Moreover, in line with a transfer effect,
CS type interacted with time (F(1,104) = 11.17, Po0.001), that is
button presses increased speciﬁcally during the CS+ presentation.
Importantly, we found a group*CS type*time interaction (F
(2,104) = 3.75, Po0.05), indicating that there were differences
between our drug and placebo groups. As can be seen in Figure 1,
in the placebo group button presses increased during the CS+
presentation as opposed to the 10 s before the CS presentation.
Both drug groups showed less of an increase in button-pressing
during the CS+ than the placebo group (Figures 1d–f). Post hoc t-
tests revealed that for the placebo group the difference between
button-pressing during the CS+ presentation was signiﬁcantly
higher than pre-CS+ presentation (t(37) = 3.68, Po0.005), as well
as signiﬁcantly higher than during the CS− presentation
(t(37) = 5.35, Po0.001). This was not the case for the amisulpride
and naltrexone groups (amisulpride: pre-CS+ versus CS+:
t(34) = 0.62, P= 0.54; CS+ versus CS-: t(34) = 1.66, P= 0.11; naltrex-
one: pre-CS+ versus CS+: t(33) = 1.92, P= 0.06; CS+ versus CS-:
t(33) = 2.03, P= 0.05). Furthermore, in both drug groups, the
difference between button-pressing for the rewarded and
unrewarded CSs during CS presentation was signiﬁcantly reduced
compared with the placebo group (amisulpride versus placebo:
t(71) = 3.01, Po0.01; naltrexone versus placebo: t(70) = 2.13,
Po0.05). There was no signiﬁcant difference between the two
drug groups (amisulpride versus naltrexone: t(67) = 0.60, P= 0.55).
Thus, cue-induced responding was reduced by both amisulpride
and naltrexone.
To assess whether the groups differed in how much they
desired M&M’s before or after the PIT task and in order to rule this
out as a potential confound for subsequent analyses, we
performed a repeated-measures ANOVA, which indicated that
there was no signiﬁcant main effect of group (F(2,104) = 0.20,
P= 0.82). Thus, the drugs did not have an impact on desire for
chocolate as such. Although the mean desire for chocolate across
groups decreased from 83.9 (pre-test) to 67.3 (post-test), in all
three groups it remained signiﬁcantly larger than 50, the midpoint
Figure 2. Proportion of smaller immediate rewards chosen in the delay-discounting task. (a) Participants in the amisulpride group chose
signiﬁcantly fewer smaller immediate rewards than those in the placebo group (*Po0.05). (b) Choice behavior of the different groups split by
high, medium and large reward magnitudes. Vertical error bars represent s.e.m.'s proportion of immediate rewards chosen; horizontal error
bars represent s.e.m.'s reward magnitudes. Higher values indicate higher reward impulsivity. CHF, Swiss Franks.
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of the scale (placebo: t(37) = 4.68, Po0.001; amisulpride:
t(34) = 3.10, Po0.01; naltrexone: t(33) = 2.98, Po0.01).
In order to test whether the groups differed in their
performance during the instrumental or Pavlovian phases, we
also compared their responding and learning during these phases
(Supplementary Table S2). Participants took on average 2.5 min
(±0.22 s.e.m.) to complete the instrumental training and
performed 113 (±0.86) button presses, or 1.33 (±0.08) button
presses per second. There were no signiﬁcant differences between
the groups in the number of button presses (F(2,104) = 0.85,
P= 0.43), the frequency of button presses (F(2,104) = 0.08, P= 0.92)
or the time until criterion (F(2,104) = 0.41, P= 0.66). Similarly, in the
Pavlovian acquisition phase, there were no signiﬁcant differences
between the groups in how well they learned the Pavlovian
contingencies of the task (F(2,104) = 2.08, P= 0.13). Overall, it
seems that, although the three groups did not differ in their desire
for chocolate or their performance during the instrumental and
Pavlovian acquisition phases, they differed in their behavior
during the transfer-test phase. Thus, learning and desire was
unaffected by the pharmacological manipulation, whereas cue-
induced responding was reduced.
Delay discounting
To test whether the dopamine and opioid receptor ligands
affected reward impulsivity, we compared the performance of the
three groups during the delay-discounting task. The groups
differed signiﬁcantly in the proportion of immediate rewards
chosen (F(2,117) = 3.18, Po0.05; Figure 2a). Post hoc t-tests
revealed that the amisulpride group chose the smaller immediate
rewards signiﬁcantly less often than the placebo group
(t(78) = 2.58, Po0.01). The difference between the naltrexone
and the placebo groups did not reach signiﬁcance (t(78) = 1.70,
P= 0.09). These data were largely the same when reward
magnitude was included as an additional factor in the analysis.
Again, we found a main effect of group (F(2,117) = 3.18, Po0.05),
but also a main effect of reward magnitude (F(2,116) = 91.03,
Po0.0001; Figure 2b), as well as a signiﬁcant reward magnitu-
de*group interaction (F(4,234) = 2.44, Po0.05). t-tests indicated
that the amisulpride group chose a lower proportion of immediate
rewards than the placebo group for all reward magnitudes (small
rewards: t(78) = 2.02, Po0.05; medium rewards: t(78) = 2.32,
Po0.05; large rewards: t(78) = 3.17, Po0.01). In contrast, although
none of the comparisons reached signiﬁcance, the difference
between naltrexone and placebo participants was highest for
small and medium rewards (small rewards: t(78) = 1.65, P= 0.102;
medium rewards: t(78) = 1.84, P= 0.07; large rewards: t(78) = 1.43,
P= 0.16). There were no signiﬁcant differences between the two
drug groups. Overall, it seems that both pharmacological
manipulations led to a reduction in discounting, with the
strongest effects for the amisulpride challenge and a nonsigniﬁ-
cant trend for the naltrexone challenge.
Relation between tasks
Although the drugs elicited similar effects on both tasks, there was
no signiﬁcant correlation between the PIT effect and the
proportion of immediate rewards chosen (r= 0.15, P= 0.14,
N= 106; Figure 3). Thus, the two tasks seem to measure different
aspects of reward-guided behavior.
Mood
Finally, in an exploratory analysis, we tested whether individual
differences in mood might have inﬂuenced cue-induced respond-
ing and reward impulsivity. A one-way ANOVA revealed that the
three groups differed in mood (F(2,116) = 3.44, Po0.05). The
mood of the amisulpride group was not signiﬁcantly different
from the mood of the naltrexone group (t(78) = 0.56, P= 0.58), but
both drug groups showed lower mood ratings than the placebo
group (placebo: 67.59 (±2.80 s.e.m.); amisulpride: 58.96 (±3.00 s.e.
m.); naltrexone: 56.30 (±3.63 s.e.m.); amisulpride: t(77) = 0.21,
Po0.05; naltrexone: t(77) = 0.25, Po0.05). We therefore re-
performed all main analyses of group differences in cue-induced
responding and reward impulsivity as analyses of covariance,
using mood as a covariate, which produced similar results. In an
exploratory correlation analysis we also investigated the inﬂuence
of mood on our two behavioral tasks. There were no signiﬁcant
correlations between mood and behavioral outcomes in the PIT
task; however, the impact of mood on delay discounting differed
between the three groups. Whereas there was no correlation in
the placebo group, elevated mood went along with a greater
number of immediate rewards chosen in the amisulpride group
(Supplementary Figure S3). In contrast, this relationship was
reversed for the naltrexone group, where mood correlated
negatively with the proportion of immediate rewards chosen.
For statistics, please refer to the Supplementary results.
DISCUSSION
To our knowledge, this is the ﬁrst study to contrast the effect of
dopamine and opioid receptor blockade on PIT and delay
discounting in healthy volunteers. Our data conﬁrm the critical
role of dopamine in both cue-induced responding and reward
impulsivity in humans by showing that dopamine D2/D3 receptor
blockade with amisulpride reduced the motivation to obtain
immediate rewards in both a PIT task and a delay-discounting
task. A blockade of μ- and κ-opioid receptors with naltrexone had
similar albeit less pronounced effects on cue-induced responding,
as well as a nonsigniﬁcant trend reduction in reward impulsivity.
Although both substances reduced mood, they differently
affected the relation between mood and delay discounting. Under
amisulpride, increased reward impulsivity was correlated with
positive mood, whereas in the naltrexone group it was associated
with negative mood, suggesting that mood might be an
important modulator of relapse risk under addiction treatment
with dopamine and opioid antagonists.
Figure 3. Absence of correlation between performance in the delay-
discounting task and the Pavlovian-instrumental transfer task.
Participants who choose more immediate rewards did not show a
proportionate increase in button-pressing during the rewarded
conditioned stimulus (CS) presentation (r= 0.15, P= 0.14, N= 106).
Placebo participants are displayed in blue, amisulpride participants
in green and naltrexone participants in red.
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Cue-induced responding
We found that amisulpride reduced cue-induced responding as
measured by PIT. These results concur with animal studies
showing that an inactivation of the ventral tegmental area, which
likely decreased dopaminergic activity in the nucleus accumbens,
reduced PIT.54,55 Moreover, systemic administration and micro-
injections in the nucleus accumbens of dopamine receptor
antagonists impair the general form of PIT,20,22 whereas intra-
accumbal microinjections of the indirect dopamine agonist
amphetamine facilitate general PIT.30,31 Only a single human
study has recently investigated the effects of a manipulation of
the dopamine system on PIT: Hebart and Gläscher21 reported that
a dietary depletion of the dopamine precursors tyrosine and
phenylalanine reduces appetitive PIT, which is in line with our
results. However, depletion of tyrosine/phenylalanine not only
decreases dopamine but also noradrenaline synthesis56 and
therefore the challenge has less speciﬁc effects on the dopamine
system compared with the selective dopamine D2/D3 receptor
antagonist amisulpride used in the present study.
The μ- and κ-opioid receptor antagonist naltrexone decreased
PIT as well. This ﬁnding is in accordance with the report that both
a stimulation of dopamine release by amphetamine as well as a
stimulation of μ-opioid receptors by DAMGO microinjection in the
nucleus accumbens increased cue-triggered levels of motivation
to pursue sucrose reward in the PIT.29 Moreover, μ-opioid receptor
knockout mice showed normal PIT, whereas δ-opioid receptor
knockout mice were impaired. Similar effects were observed when
μ- or δ-opioid receptor antagonists were injected into the nucleus
accumbens.28 One human study has investigated opioid effects on
cue reactivity in non-treatment-seeking alcoholics.32 The same
dosage of naltrexone as used in the current study, over a 7-day
period, produced no changes in craving, but led to a reduction in
alcohol cue-induced neural activation in the ventral striatum. Our
ﬁndings extend these results to healthy participants, separate the
drug effect from the disorder effect and thereby provide a clearer
picture of opioid effects on cue-induced responding
Reward impulsivity
Our ﬁnding of reduced reward impulsivity under amisulpride is in
line with previous animal studies showing that the indirect
dopamine agonists amphetamine34,35 and cocaine36 increase
reward impulsivity, although also contradictory results exist.33
Moreover, one small human study (n= 13) has also revealed
increased reward impulsivity with indirect catecholamine agonism
by L-DOPA (Pine et al.;19 but see De Wit et al.17 for opposing
results with amphetamine, as well as Hamidovic et al.37 for null
effects using oramipexole), but found no effect with the
unselective dopamine antagonist haloperidol. Our results add to
this literature by showing that selective blockade of D2/D3
receptors can reduce reward impulsivity.
Reward impulsivity was moderately reduced by naltrexone,
although the reduction did not reach signiﬁcance. Only few
studies have investigated the effects of opioid challenges on
reward impulsivity in humans and animals. For example, in one
animal study the μ-opioid receptor agonist morphine dose-
dependently increased reward impulsivity, whereas naltrexone
alone did not affect the value of delayed rewards but blocked the
effects of morphine.25 Two very small human studies showed no
signiﬁcant effects of naltrexone on reward impulsivity (nine
abstinent alcoholics and nine healthy controls;38 nine abstinent
alcoholics and ten healthy controls57). Interestingly, a PET study
using a μ-opioid receptor-selective radiotracer revealed that
individuals with high trait impulsivity showed elevated density
of μ-opioid receptors in regions underpinning reward impulsivity,
such as the nucleus accumbens and the amygdala.26
It is important to note that the primary effects of amisulpride
and naltrexone on reward impulsivity, cue-induced responding
and even mood were relatively similar. This is in line with the
recently reported common involvement of the dopamine and the
opioid system in the direct control of drug-‘wanting’ behavior.29
On the other hand, naltrexone has been shown to block
dopamine release in the nucleus accumbens, induced, for
example, by alcohol58 or feeding.59 Indeed, the mesolimbic opioid
and dopamine systems appear to be closely linked. For example,
opiates inhibit GABAergic interneurons in the midbrain and
thereby disinhibit dopamine neurons.60,61 Consequently, naltrex-
one may have inﬂuenced behavior indirectly by a modulation of
accumbal dopamine release. Invasive methods would be required
to completely disentangle the direct from the dopamine-
mediated impact of opioid receptor stimulation and blockade
on reward impulsivity. However, the observation that the two
drug challenges differentially affected the relation between mood
and reward impulsivity is more in line with independent actions of
naltrexone rather than actions that are mediated through an
effect on dopamine neurons.
Mood effects
On average, the mood of the amisulpride and of the naltrexone
group was lower than the mood of the placebo group. This effect
is plausible for naltrexone, for which dysphoria has been reported
as a common side effect;62 however, the negative mood effect of
amisulpride is surprising, given that the compound has been
shown to be an effective antidepressant.63 Although these
differences could not account for our ﬁndings when we included
mood as a covariate, it is worth noting that more positive mood
has previously been associated with increased reward
impulsivity.64 Conversely, anhedonia is associated with reduced
reward impulsivity65 and reduced willingness to exert effort for
reward.66 More importantly, we found that both drug challenges
exerted opposite effects on the relation between mood and
reward impulsivity but had no effects on the relation between
mood and cue-induced responding. This ﬁnding, together with
the absence of a relation between cue-induced responding and
reward impulsivity across the total study sample (Figure 3),
suggests that cue reactivity and reward impulsivity may reﬂect
distinct reward processes (see also Supplementary Discussion). It is
conceivable that cue-induced responding is more strongly related
to stimulus-induced value prediction, whereas reward impulsivity
may reﬂect a bias of immediate rewards on the computation of
decision value.
Limitations
The following limitations should be kept in mind when consider-
ing our study. (1) Given that the PIT task cannot reasonably be
repeated within an individual, we employed a between-subject
design, although a within-subject design would have been
advantageous regarding the reliability of the results. However,
we aimed to compensate this limitation by investigating relatively
large samples. (2) In order to maximize the number of subjects in
each group, we only tested single doses of the two blockers.
Varying the dosage may provide information about the relative
inﬂuence of the dopamine and opioid systems on cue-induced
responding and reward impulsivity. (3) Amisulpride blocks not
only dopamine D2/3 receptors but also 5-HT7 receptors.67 In this
regard it is worth noting that acute serotonin (tryptophan)
depletion reduces reactivity to aversive cues, but has no effects
on appetitive cues in general versions of PIT,68 which together
with our results is in line with the notion that the dopamine and
the serotonin systems have opposing roles in appetitive and
aversive value processing. (4) The version of our PIT task does not
allow to distinguish general forms of cue-induced responding
from outcome-speciﬁc forms.69,70 This permits only limited
comparisons to animal studies that differentiate between these
two types of PIT. (5) Our measure of mood as a single-item
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question at the end of the study provides only a global measure of
mood state. Future studies should therefore apply a more
sensitive measure of mood and measure baseline mood in order
to conﬁrm the relationship between mood and reward impulsivity
and the modulatory effects of naltrexone.
CONCLUSIONS
Although animal research provided promising ﬁndings,71 the
efﬁcacy of dopamine receptor antagonists for the treatment of
addiction in humans appears to be limited.9 Our data suggest that
it may be worth exploring the usefulness of the more speciﬁc D2/
D3 dopamine receptor antagonist amisulpride, particularly in
patients with increased reactivity to drug cues and elevated
reward impulsivity. Moreover, it could be of interest to further
explore the relationship of mood and reward impulsivity under
naltrexone and amisulpride, as individual mood of the patient
could potentially prove to be a relevant factor when deciding
between treatment with amisulpride or naltrexone. In conclusion,
we show that the opioid system contributes to increased
responding to reward cues, whereas the effects on delay
discounting were less pronounced in our study. In contrast, the
dopamine system was involved in both responding to reward-
associated cues and in delay discounting.
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